Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Meiragtx Holdings plc
Headquarters: New York, NY, United States of America
Website: https://meiragtx.com/
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Alexandria Forbes, PhD
Number Of Employees: 381
Enterprise Value: $406,356,130
PE Ratio: -2.88
Exchange/Ticker 1: NASDAQ:MGTX
Exchange/Ticker 2: N/A
Latest Market Cap: $483,380,480
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Nov 1, 2024
Discovery & Translation
Dynamic range: the key to MeiraGTx’s quest to control genes with pills
Company’s first goals are to improve GLP-1s and CAR Ts with the ability to go from zero to very high expression, on demand
BioCentury | Oct 15, 2024
Product Development
MeiraGTx data bring early POC for Parkinson’s gene therapy and localized gene expression strategy
In BioCentury’s latest Clinical Report, Skysona’s cancer risk comes into focus, GSK’s IL-5 meets in rhinosinusitis, Jasper’s c-Kit improves hives, and more
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | Apr 2, 2024
Product Development
Vectorized biologics: are patients and payers ready to swap biologics for gene therapies?
Gene therapy vectors that deliver biologic drugs enter late-state clinical trials
BioCentury | Dec 22, 2023
Regulation
Dec. 21 Quick Takes: FDA’s approval of eplontersen sets up challenge to Alnylam’s Amvuttra
Plus: Cytokinetics gains on takeout talk and updates from Lilly-Fauna, Sanofi, Illumina, BioMarin, MeiraGTx and more
BioCentury | Oct 31, 2023
Finance
Oct. 30 Quick Takes: VCs pile in for MapLight’s $225M series C
Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more
BioCentury | Jun 12, 2023
Emerging Company Profile
Syncona wraps up three ocular gene therapies, launches Beacon in second shot at XLRP
VCs back start-up in £96M series A, joining AGTC takeout with pair of preclinical programs
BioCentury | Mar 28, 2023
Product Development
Gene therapy: If you’re not first, are you last?
How gene therapy CEOs are thinking about the competitive landscape, and where market opportunity exists
Items per page:
1 - 10 of 35